First Turn Management LLC Has $17.94 Million Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

First Turn Management LLC trimmed its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 18.3% in the third quarter, HoldingsChannel reports. The firm owned 114,247 shares of the company’s stock after selling 25,533 shares during the period. TransMedics Group makes up 2.8% of First Turn Management LLC’s portfolio, making the stock its 12th biggest position. First Turn Management LLC’s holdings in TransMedics Group were worth $17,937,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. International Assets Investment Management LLC bought a new stake in TransMedics Group during the second quarter worth $47,000. USA Financial Formulas bought a new stake in shares of TransMedics Group in the 3rd quarter valued at $55,000. J.Safra Asset Management Corp grew its position in TransMedics Group by 649.2% in the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after purchasing an additional 383 shares during the period. Signaturefd LLC boosted its holdings in TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after acquiring an additional 93 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its holdings in shares of TransMedics Group by 187.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock worth $76,000 after buying an additional 316 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

TMDX has been the topic of several research analyst reports. Piper Sandler restated an “overweight” rating and issued a $180.00 price objective on shares of TransMedics Group in a research report on Tuesday, October 29th. JPMorgan Chase & Co. dropped their price objective on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 29th. TD Cowen lowered their price objective on TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research report on Monday. Robert W. Baird reduced their price objective on TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 29th. Finally, Stephens lifted their target price on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $139.30.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, insider Nicholas Corcoran sold 10,000 shares of TransMedics Group stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the transaction, the insider now directly owns 21,105 shares of the company’s stock, valued at $3,714,902.10. The trade was a 32.15 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the sale, the chief executive officer now owns 61,643 shares in the company, valued at $9,457,269.06. This represents a 12.27 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 36,958 shares of company stock worth $5,230,528. 7.00% of the stock is owned by corporate insiders.

TransMedics Group Stock Up 0.6 %

Shares of TransMedics Group stock opened at $80.93 on Tuesday. The company has a market cap of $2.72 billion, a P/E ratio of 86.10 and a beta of 2.08. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group, Inc. has a one year low of $66.76 and a one year high of $177.37. The firm has a fifty day moving average of $125.63 and a two-hundred day moving average of $139.55.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The company had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business’s revenue for the quarter was up 63.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.12) EPS. On average, analysts forecast that TransMedics Group, Inc. will post 1.07 earnings per share for the current year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.